HUP0103994A3 - Method of stimulating prosaposin receptor activity - Google Patents

Method of stimulating prosaposin receptor activity

Info

Publication number
HUP0103994A3
HUP0103994A3 HU0103994A HUP0103994A HUP0103994A3 HU P0103994 A3 HUP0103994 A3 HU P0103994A3 HU 0103994 A HU0103994 A HU 0103994A HU P0103994 A HUP0103994 A HU P0103994A HU P0103994 A3 HUP0103994 A3 HU P0103994A3
Authority
HU
Hungary
Prior art keywords
receptor activity
prosaposin receptor
stimulating
stimulating prosaposin
activity
Prior art date
Application number
HU0103994A
Other languages
Hungarian (hu)
Original Assignee
Myelos Corp San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelos Corp San Diego filed Critical Myelos Corp San Diego
Publication of HUP0103994A2 publication Critical patent/HUP0103994A2/en
Publication of HUP0103994A3 publication Critical patent/HUP0103994A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0103994A 1998-09-09 1999-09-09 Method of stimulating prosaposin receptor activity HUP0103994A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14997798A 1998-09-09 1998-09-09
PCT/US1999/020829 WO2000014113A2 (en) 1998-09-09 1999-09-09 Method of stimulating prosaposin receptor activity

Publications (2)

Publication Number Publication Date
HUP0103994A2 HUP0103994A2 (en) 2002-02-28
HUP0103994A3 true HUP0103994A3 (en) 2004-03-01

Family

ID=26795763

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103994A HUP0103994A3 (en) 1998-09-09 1999-09-09 Method of stimulating prosaposin receptor activity

Country Status (9)

Country Link
EP (1) EP1112090A2 (en)
JP (1) JP2002524468A (en)
KR (1) KR20010079770A (en)
AU (1) AU6141599A (en)
BR (1) BR9913870A (en)
CA (1) CA2341325A1 (en)
HK (1) HK1039744A1 (en)
HU (1) HUP0103994A3 (en)
WO (1) WO2000014113A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
CN112481269A (en) * 2017-10-03 2021-03-12 普利维尔治疗公司 Gene therapy for lysosomal disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
EP1179350A3 (en) * 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
CA2304108A1 (en) * 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists

Also Published As

Publication number Publication date
WO2000014113A2 (en) 2000-03-16
AU6141599A (en) 2000-03-27
CA2341325A1 (en) 2000-03-16
KR20010079770A (en) 2001-08-22
WO2000014113A3 (en) 2000-11-16
HK1039744A1 (en) 2002-05-10
JP2002524468A (en) 2002-08-06
HUP0103994A2 (en) 2002-02-28
BR9913870A (en) 2001-07-24
EP1112090A2 (en) 2001-07-04

Similar Documents

Publication Publication Date Title
HUP0200495A3 (en) Method of treating eating disorders
EP0946180A4 (en) Method for stimulating bone formation
PL341053A1 (en) Method of obtaining n-propanol
PL330843A1 (en) Method of obtaining 17-esters of 9alpha, 21-dihalo-pregnano-11beta, 17alpha-diol-20-ones
PL335163A1 (en) Method of obtaining substituted thiazolydinodione
PL335074A1 (en) Method of obtaining eprosartane
PL335075A1 (en) Method of obtaining eprosartane
PL338354A1 (en) Method of obtaining avermectin compounds
HUP0103994A3 (en) Method of stimulating prosaposin receptor activity
HUP0002389A3 (en) Method of producing c-nucleosides
PL334901A1 (en) Method of obtaining benzothiazolones
IL141865A0 (en) Method of stimulating prosaposin receptor activity
ZA982579B (en) Method of stimulating nerve regeneration
PL339188A1 (en) Method of obtaining oxaphosphorin-2-amines
HUP0100612A3 (en) Method of screening therapeutic agents
PL340915A1 (en) Method of obtaining azacycloalkylalkanoyl pseudotetrapeptides
GB9812941D0 (en) Method of treatment
PL336266A1 (en) Method of obtaining epsilon-caprolactams
PL341302A1 (en) Method of obtaining chlorobenzoxazoles
PL335887A1 (en) Method of obtaining arylaminotriazole pyridines
PL340497A1 (en) Method of obtaining formylimidazoles
EP1107774A4 (en) Ramp2a: receptor activity modifying protein-2a
GB9822681D0 (en) Method of treatment
PL339761A1 (en) Method of obtaining aminocabonylic genezerolin of selective activity against cerebral cholinesterase
PL322539A1 (en) Method of obtaining substituted 1-cycloalkenes